Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.
Douglas B. Flora, MD, LSSBB
Advertisement
Douglas B. Flora, MD, LSSBB, is the executive medical director of Oncology Services and the Robert and Dell Ann Sathe Endowed Chair in Oncology at St. Elizabeth Healthcare.
Articles by Douglas B. Flora, MD, LSSBB
Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.
Douglas B. Flora, MD, LSSBB, discusses the rationale for assessing BXQ-350 plus mFOLFOX7 and bevacizumab in a phase 1/2 trial of patients with mCRC.
Advertisement
Latest Updated Articles
Dr Flora on the Implications of Emerging AI Models for Oncology CarePublished: April 21st 2025 | Updated:
Dr Flora on the Mechanism of Action of BXQ-350 in Newly Diagnosed CRCPublished: February 26th 2025 | Updated:
Dr Flora on the Potential Role of AI in Clinical Trial Screening and Design for OncologyPublished: September 28th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5